Literature DB >> 12174882

High density lipoprotein complexes as delivery vehicles for anticancer drugs.

Andras G Lacko1, Maya Nair, Sulabha Paranjape, Shemedia Johnso, Walter J McConathy.   

Abstract

MATERIALS AND METHODS: Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes.
RESULTS: Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines.
CONCLUSION: Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174882

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

Review 1.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

2.  Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF).

Authors:  Walter J McConathy; Sulabha Paranjape; Linda Mooberry; Sabitha Buttreddy; Maya Nair; Andras G Lacko
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 3.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Authors:  Kaylin M McMahon; Linda Foit; Nicholas L Angeloni; Francis J Giles; Leo I Gordon; C Shad Thaxton
Journal:  Cancer Treat Res       Date:  2015

4.  Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells.

Authors:  Xiao Gu; Wenli Zhang; Jianping Liu; John P Shaw; Yuanjun Shen; Yiming Xu; Hui Lu; Zimei Wu
Journal:  AAPS PharmSciTech       Date:  2011-09-17       Impact factor: 3.246

5.  A Fluorescence Study of the Interaction of Anticancer Drug Molecule Doxorubicin Hydrochloride in Pluronic P123 and F127 Micelles.

Authors:  Sagar Kumar Behera; Maneesha Esther Mohanty; Monalisa Mohapatra
Journal:  J Fluoresc       Date:  2020-10-10       Impact factor: 2.217

6.  Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles.

Authors:  Qiaoya Lin; Juan Chen; Kenneth K Ng; Weiguo Cao; Zhihong Zhang; Gang Zheng
Journal:  Pharm Res       Date:  2013-04-27       Impact factor: 4.200

Review 7.  High-density lipoproteins for the systemic delivery of short interfering RNA.

Authors:  Kaylin Marie McMahon; Colby Shad Thaxton
Journal:  Expert Opin Drug Deliv       Date:  2013-12-09       Impact factor: 6.648

Review 8.  HDL and microRNA therapeutics in cardiovascular disease.

Authors:  Danielle L Michell; Kasey C Vickers
Journal:  Pharmacol Ther       Date:  2016-09-03       Impact factor: 12.310

9.  Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.

Authors:  Mian M K Shahzad; Lingegowda S Mangala; Hee Dong Han; Chunhua Lu; Justin Bottsford-Miller; Masato Nishimura; Edna M Mora; Jeong-Won Lee; Rebecca L Stone; Chad V Pecot; Duangmani Thanapprapasr; Ju-Won Roh; Puja Gaur; Maya P Nair; Yun-Yong Park; Nirupama Sabnis; Michael T Deavers; Ju-Seog Lee; Lee M Ellis; Gabriel Lopez-Berestein; Walter J McConathy; Laszlo Prokai; Andras G Lacko; Anil K Sood
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

10.  High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer.

Authors:  Baoying Yuan; Changshun Wu; Xingwen Wang; Dan Wang; Huiling Liu; Ling Guo; Xiang-An Li; Junqing Han; Hong Feng
Journal:  Tumour Biol       Date:  2015-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.